Abstract 16224: Efficacy of Torsemide versus Furosemide in Heart Failure. A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Mohamed Eid, Kirolos Barssoum, Mostafa R Mostafa, Andrew Takla, Mostafa Najim, Sarah Mohamed, Mohamed Diab, Sarath Lal Mannumbeth Renjithlal, Hani Jneid- Physiology (medical)
- Cardiology and Cardiovascular Medicine
There is conflicting evidence regarding how torsemide and furosemide differ in their effects on heart failure outcomes. Therefore, we conducted a meta-analysis of randomized controlled trials to compare the therapeutic efficacy of furosemide versus torsemide in the management of heart failure.
Methods: MEDLINE/PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were queried for studies comparing furosemide to torsemide in heart failure from inception through January 2023. Outcomes of interest included all-cause mortality, hospitalization due to heart failure, and weight change.
Results: Our analysis included 10 RCTs comprising 4011 patients, of whom 2019 were treated with furosemide and 1992 patients were treated with torsemide. There was no significant difference between the groups in terms of all-cause mortality (OR 0.99; 95% CI, 0.97-1.02; p = 0.66; I2 = 0.03%); heart failure hospitalization (OR 0.96; 95% CI, 0.87- 1.06; p = 0.38; I2 = 89%) and weight change (mean difference -0.15; 95% CI, -0.82-0.52; p = 0.66; I2 = 94%).
Conclusion: Furosemide and torsemide have a similar impact on mortality, hospitalization due to heart failure, and weight change in patients with congestive heart failure